Prelude Capital Management, LLC Biomarin Pharmaceutical Inc Call Options Transaction History

Prelude Capital Management, LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2020 Nov 16, 2020	SELL	$71.87 - $131.03 $7,187 - $13,103	-100 Reduced 25.0%	300 $23,000
Q2 2020 Aug 14, 2020	SELL	$79.55 - $124.22 $47,730 - $74,532	-600 Reduced 60.0%	400 $49,000
Q4 2017 Feb 14, 2018	SELL	$80.76 - $95.13 $40,380 - $47,565	-500 Reduced 33.33%	1,000 $89,000
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $120,899 - $142,425	1,500	1,500 $140,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.